Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Leo Gordon
Northwestern University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Northwestern University
Chicago, Illinois, United States
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- Decatur Memorial Hospital
Decatur, Illinois, United States
- Northshore University Healthsystem-Evanston Hospital
Evanston, Illinois, United States
- Ingalls Memorial Hospital
Harvey, Illinois, United States
- Illinois Cancercare-Peoria
Peoria, Illinois, United States
- Southern Illinois University
Springfield, Illinois, United States
- Fort Wayne Medical Oncology and Hematology Inc-Parkview
Fort Wayne, Indiana, United States
- Indiana University/melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
- University of Maryland/greenebaum Cancer Center
Baltimore, Maryland, United States
- Tufts Medical Center
Boston, Massachusetts, United States
- University of Massachusetts Memorial Health Care
Worcester, Massachusetts, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Saint John'S Mercy Medical Center
St Louis, Missouri, United States
- Weill Medical College of Cornell University
New York, New York, United States
- M D Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2010
- Primary completion
- 28 Feb 2014
- Completion
- 31 May 2014
- Last update posted
- 3 Feb 2016
- Registered enrollment
- 16
- Registry id
- NCT01278615
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.